Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Alectinib Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alecensaro (alectinib) and Risk of Severe Hypertriglyceridemia
    Alecensaro (alectinib) and Risk of Severe Hypertriglyceridemia

    22 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7204178

    FIRSTWORD PHARMA
    22 Apr 2026
    Share Share
    Natco’s Generics Alectinib Receives Approval in US
    Natco’s Generics Alectinib Receives Approval in US

    25 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217441

    FDA
    25 Feb 2026
    Share Share
    Roche’s Alecensa receives NICE to treat ALK-positive lung cancer
    Roche’s Alecensa receives NICE to treat ALK-positive lung cancer

    22 Oct 2024

    // PMLIVE

    https://pmlive.com/pharma_news/roches-alecensa-receives-nice-recommendation-to-treat-alk-positive-lung-cancer/

    PMLIVE
    22 Oct 2024
    Share Share
    Chugai's Alecensa Approved In Japan For Early-Stage ALK+ NSCLC
    Chugai's Alecensa Approved In Japan For Early-Stage ALK+ NSCLC

    29 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=172159&sid=2

    PHARMABIZ
    29 Aug 2024
    Share Share
    Taiwan FDA Approves Chugai's Alecensa For Early Stage ALK+ NSCLC
    Taiwan FDA Approves Chugai's Alecensa For Early Stage ALK+ NSCLC

    03 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=171663&sid=2

    PHARMABIZ
    03 Aug 2024
    Share Share
    EU Approves Roche's Alecensa As Targeted Adjuvant For ALK+ Lung Cancer
    EU Approves Roche's Alecensa As Targeted Adjuvant For ALK+ Lung Cancer

    10 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/10/2895717/0/en/European-Commission-approves-Roche-s-Alecensa-as-the-first-and-only-targeted-adjuvant-treatment-for-people-with-ALK-positive-early-stage-lung-cancer.html

    GLOBENEWSWIRE
    10 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.